RA
CRL icon

Royce & Associates’s Charles River Laboratories CRL Stock Holding History

Royce & Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-84,361
Closed -$13.2M – 773
2025
Q3 		$13.2M Sell
84,361
-1,279
-1% -$203K 0.13% 238
2025
Q2 		$13M Buy
85,640
+81,500
+1,969% +$10.9M 0.13% 231
2025
Q1 		$623K Buy
+4,140
New +$694K 0.01% 715
2024
Q2 		– Sell
-15,592
Closed -$4.22M – 884
2024
Q1 		$4.22M Buy
15,592
+1,617
+12% +$386K 0.04% 533
2023
Q4 		$3.3M Buy
+13,975
New +$2.75M 0.03% 572

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Royce & Associates's CRL Position: Q4 2025 in Review

Royce & Associates sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 84,361 shares — an estimated $13.2M sold.

Royce & Associates first reported a position in CRL in Q4 2023 and held it in 5 quarters. The position peaked at $13.2M in Q3 2025. 582 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • Royce & Associates reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
  • Royce & Associates sold 84,361 Charles River Laboratories shares in Q4 2025, an estimated $13.2M.
  • Royce & Associates first reported a position in Charles River Laboratories in Q4 2023 and held it in 5 quarters.
  • Royce & Associates's Charles River Laboratories position peaked at $13.2M in Q3 2025.
  • 582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Royce & Associates's 13F filing for Q4 2025, filed 9 Feb 2026.